Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107605 | 0.84 | ALDH1A1 (0.64) | POLBKDM4EALDH1A1RAB9AGAA | |
| SCHEMBL7383878 | 0.83 | DRD4 (0.60) | DRD2DRD4SIGMAR1ABCB1 | |
| SCHEMBL4491366 | 0.83 | HTR7 (0.57) | DRD2DRD4POLBALDH1A1HTR7 | |
| SCHEMBL4557706 | 0.80 | CHRM1 (0.60) | DRD2DRD4POLBKDM4EALDH1A1 | |
| SCHEMBL13089316 | 0.79 | ALDH1A1 (0.66) | DRD2ALDH1A1HTR7 | |
| SCHEMBL14577894 | 0.78 | HTR7 (0.54) | DRD2DRD4POLBKDM4EALDH1A1 | |
| SCHEMBL4496608 | 0.77 | CHRM1 (0.69) | DRD2DRD4SIGMAR1ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL5358225 | 0.77 | ALDH1A1 (0.56) | DRD2DRD4POLBKDM4EALDH1A1 | |
| SCHEMBL27688476 | 0.76 | HDAC8 (0.68) | ALDH1A1 | |
| SCHEMBL5857750 | 0.76 | CACNA1G (0.60) | ALDH1A1HTR7MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485651-B2 | Compounds with activity on muscarinic receptors | ACADIA PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | BRANN MARK | 2008-05-08 | — | — | US | disclosed |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | BRANN MARK (US) | 2003-07-31 | — | — | US | disclosed |
| US-6528529-B1 | 4-Methoxy-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine | ACADIA PHARMACEUTICALS INC. | 2003-03-04 | — | — | US | disclosed |
| WO-2001005763-A2 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
| EP-1068185-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | Acadia Pharmaceuticals Inc. (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050247-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | ACADIA PHARMACEUTICALS, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | CHRM3, CHRM2, CHRM1 | DRD2 470/4885DRD4 824/4885SIGMAR1 219/4885 |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | CHRM3, CHRM2, CHRM1 | DRD2 470/4885DRD4 824/4885SIGMAR1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.